Skip to main content
. 2024 Nov 26;46(12):13526–13541. doi: 10.3390/cimb46120808

Figure 3.

Figure 3

Comparison of the cell viability (%) of HaCaT (A) and HFDPC (B) cells between the control and the DME treatment groups [4,12,13,14,16,26,29].